Search Results 121-130 of 23160 for B cell lymphomas
Burkitt lymphoma. Human Pathology. 2024; doi:10.1016/j.humpath.2024.105703. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org ...
... lymphoma (NHL; B or T-cell). CCS1477 is a potent, selective and orally bioavailable inhibitor of the bromodomain of p300 and CBP, critical transcriptional ...
The therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal ...
Slager's B-Cell Lymphoproliferative Disorders Laboratory, including information about chronic lymphocytic leukemia, lymphoma, multiple myeloma, the National ...
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem ...
Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...
Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...
Chimeric antigen receptor (CAR)-T cell therapy trains the immune system cells to fight follicular lymphoma. ... B-cell lymphomas. National Comprehensive Cancer ...
Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma. Participation ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.